TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02040090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active rabies vaccine (US-FDA approved)
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active rabies vaccine (US-FDA approved)
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Study: NCT03656731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast cancer exercise intervention
Description: The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session.
Study: NCT03135457

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous RBC transfusion
Description: Autologous RBC transfusion 300ml 10 ml/min

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous RBC transfusion
Description: Autologous RBC transfusion 300ml 10 ml/min

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline transfusion
Description: Saline transfusion 300ml 10ml/min

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline transfusion
Description: Saline transfusion 300ml 10ml/min
Study: NCT01265823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
Study: NCT03714022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive abatacept at a single dose 750 mg as IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Participants will receive abatacept at a single dose 750 mg as IV infusion.
Study: NCT00715741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water
Description: FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 0.3 without PEEP
Description: FiO2 0.3 without PEEP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 >0.9 with 3-5 cm water PEEP
Description: FiO2 \>0.9 with 3-5 cm water PEEP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 >0.9 without PEEP
Description: FiO2 \>0.9 without PEEP
Study: NCT00738452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: Approximately 2 days and 3-5 days post infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Description: Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
Study: NCT02120885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
Study: NCT03754361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated peritoneal dialysis
Description: peritoneal dialysis administered by a cycler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IHD
Description: HD 4hour 2-3times per week
Study: NCT04355429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril 25mg
Description: Drug administration
Study: NCT02743390

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline for 2 hours (250mL)
Study: NCT04055311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Resource Information Support (CRIS)
Description: Intervention support is patient initiated and accessed as needed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Enhanced
Description: Usual care is enhanced with the addition of the NCI Facing Forward brochure
Study: NCT01876537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hardware wound healing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Surgery
Study: NCT00230022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computer-delivered intervention
Description: 20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
Study: NCT04142164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MacInfo presentation
Description: Presentation about intravitreal drug injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo presentation
Description: Placebo presentation
Study: NCT04250350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study: NCT04476342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal invasive cardiopulmonary bypass (MICPB) system
Description: The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
Study: NCT00534079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa (Pulmozyme)
Description: 1 x 2,5 ml per day, inhalation use, for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dornase alfa (Pulmozyme)
Description: 1 x 2,5 ml per day, inhalation use, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study: NCT04108975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle non reapproximation during CS
Description: During CS rectus muscle non reapproximation will be done.
Study: NCT05990283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket shield technique
Description: For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
Study: NCT00534079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study: NCT03487341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord drainage
Description: Cord drainage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord clamping
Description: Cord clamping
Study: NCT02641106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy
Description: Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person DOT
Description: Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
Study: NCT00618384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
Study: NCT01275651

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02778334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey
Description: Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3).
Study: NCT01721915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00327743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel
Description: IV infusion on Day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral, twice daily, Day 1-Day 14 of a 21-day cycle
Study: NCT02161003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Injection Technique
Description: Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Isolation
Description: From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
Study: NCT02137109

Intervention type: DRUG
Intervention: natalizumab
Description: Administered as specified in the treatment arm.
Study: NCT03259828

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant image-guided radiotherapy
Description: Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
Study: NCT02819245

Intervention type: PROCEDURE
Group type: OTHER
Intervention: posterior correction and fusion
Study: NCT02781857

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT02433925

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01287091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral capsule dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet dose in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral repeating dose
Study: NCT04167124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-sensor lifestyle intervention
Study: NCT00459706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel 50 mg Prefilled Syringe
Description: Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel 50 mg Autoinjector
Description: Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
Study: NCT02128425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT02168374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment
Description: Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment
Description: Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Indirect pulp treatment
Description: Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
Study: NCT04599725

Intervention type: DRUG
Intervention: medical abortion
Description: medical abortion
Study: NCT00090987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg orally once a day for up to 6 months.
Study: NCT00492596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AttenueX IntraVesical System
Description: Insertion of the Solace AttenueX Intravesical System on Day 0

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AttenueX IntraVesical System
Description: Insertion of the Solace AttenueX Intravesical System on Day 0

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
Study: NCT02564640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: videolaryngoscope
Description: patients intubated by using the videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: patients intubated by using the Macintosh laryngoscope
Study: NCT04154462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scribes
Description: Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
Study: NCT02140528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injection
Description: Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04642677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthcare provider's recommended communication with sympathy and printed paper
Description: Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation.
Study: NCT02760030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Given PO
Study: NCT02895308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducation
Description: The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation
Description: The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.